Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

5-AZA effective for myelodysplastic syndromes in elderly adults

15 Jan 2020

In elderly adults with intermediate- or high-risk myelodysplastic syndromes (MDS) or oligoblastic acute myeloid leukaemia (AML), 5-azacytidine (5-AZA) may be an effective treatment option, a recent study has found.

Researchers conducted a retrospective analysis of 102 elderly adults (median age, 83 years) who had intermediate-2 or high-risk MDS. Frontline treatment was carried out with a single dose of 75 mg/m2/day of 5-AZA, given for seven consecutive days. The study outcomes were treatment response, overall survival and time to transformation to AML.

The overall response rate was 44.3 percent, with a median response duration of 12 months. Sixty-three participants had available data for 5-AZA relative dose intensity (RDI); of these, 81.0 percent (n=63) were able to take the standard dose. Almost half (24 of 52; 46.2 percent) of patients who were dependent at baseline achieved transfusion independence.

Over a median follow-up of 17 months, the median AML-free survival time was estimated to be 49 months. This turned out to be longer in participants who had responded to the treatment (failure vs overall response: hazard ratio [HR], 7.56, 95 percent confidence interval [CI], 2.61–21.95; p<0.001). 5-AZA RDI did not significantly affect AML-free survival (p=0.51).

On the other hand, the medial overall survival estimate was 17 months, similarly greater in those who responded to 5-AZA treatment (failure vs overall response: HR, 6.00, 95 percent CI, 3.07–11.70; p<0.001). RDI was not significantly predictive of overall survival.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.